Literature DB >> 2534679

[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements].

S Giménez-Roldán, D Mateo.   

Abstract

Dopaminergic oversupply relative to intrinsic striatal cell loss is thought to underlie the involuntary movements of Huntington's disease (HD). Tetrabenazine (TBZ) and haloperidol, two antidopaminergic compounds differing in their mechanism of action on the nigrostriatal pathway were compared in 11 HD patients in their ability to decrease the choreatic movements in a single-blind cross-over study. Though improvement in chorea scores over baseline values was greater under TBZ (46.3 +/- 23.4) than haloperidol (28.6 +/- 47.7), the difference did not reach statistical significance (Student t tests). All 11 patients improved to some extent during the TBZ phase, and in 6 it was greater than while under haloperidol. However, haloperidol reduction in the chorea scores was significantly greater in 3 patients, while there was no difference in 2 other cases. Severe depression occurred in 3 patients under TBZ, in one leading to attempting suicide, while tardive dyskinesia complicated haloperidol therapy in 3 patients. The later drug could be an alternative therapy for those patients in whom TBZ provides unsatisfactory control of the choreatic movements, but it might be the drug of choice in cases with associated depressive illness or organic psychosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2534679

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  9 in total

1.  Therapeutics in Huntington's Disease.

Authors:  Annie Killoran; Kevin M Biglan
Journal:  Curr Treat Options Neurol       Date:  2012-02-08       Impact factor: 3.598

Review 2.  Therapeutic approaches to Huntington disease: from the bench to the clinic.

Authors:  Nicholas S Caron; E Ray Dorsey; Michael R Hayden
Journal:  Nat Rev Drug Discov       Date:  2018-09-21       Impact factor: 84.694

Review 3.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

Review 4.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 5.  An Update on the Treatment of Chorea.

Authors:  Erin Feinstein; Ruth Walker
Journal:  Curr Treat Options Neurol       Date:  2018-09-25       Impact factor: 3.598

Review 6.  Symptomatic treatment of Huntington disease.

Authors:  Octavian R Adam; Joseph Jankovic
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

Review 7.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 8.  Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.

Authors:  Thirunavukkarasu Velusamy; Archana S Panneerselvam; Meera Purushottam; Muthuswamy Anusuyadevi; Pramod Kumar Pal; Sanjeev Jain; Musthafa Mohamed Essa; Gilles J Guillemin; Mahesh Kandasamy
Journal:  Oxid Med Cell Longev       Date:  2017-01-12       Impact factor: 6.543

9.  Tetrabenazine in the treatment of Huntington's disease.

Authors:  Diana Paleacu
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.